Aoudjit Fawzi, Vuori Kristiina
Pavillon CHUL, Centre de Recherche du CHUQ and Faculté de Médecine, Université Laval, Québec, QC, Canada G1V 4G2.
Chemother Res Pract. 2012;2012:283181. doi: 10.1155/2012/283181. Epub 2012 Apr 11.
Resistance to apoptosis and chemotherapy is a hallmark of cancer cells, and it is a critical factor in cancer recurrence and patient relapse. Extracellular matrix (ECM) via its receptors, the integrins, has emerged as a major pathway contributing to cancer cell survival and resistance to chemotherapy. Several studies over the last decade have demonstrated that ECM/integrin signaling provides a survival advantage to various cancer cell types against numerous chemotherapeutic drugs and against antibody therapy. In this paper, we will discuss the major findings on how ECM/integrin signaling protects tumor cells from drug-induced apoptosis. We will also discuss the potential role of ECM in malignant T-cell survival and in cancer stem cell resistance. Understanding how integrins and their signaling partners promote tumor cell survival and chemoresistance will likely lead to the development of new therapeutic strategies and agents for cancer treatment.
对细胞凋亡和化疗的抗性是癌细胞的一个标志,并且是癌症复发和患者复发的关键因素。细胞外基质(ECM)通过其受体整合素,已成为促进癌细胞存活和对化疗产生抗性的主要途径。过去十年的多项研究表明,ECM/整合素信号传导为各种癌细胞类型提供了针对多种化疗药物和抗体疗法的生存优势。在本文中,我们将讨论关于ECM/整合素信号传导如何保护肿瘤细胞免受药物诱导的细胞凋亡的主要发现。我们还将讨论ECM在恶性T细胞存活和癌症干细胞抗性中的潜在作用。了解整合素及其信号传导伙伴如何促进肿瘤细胞存活和化疗抗性,可能会导致开发新的癌症治疗策略和药物。